VIVUS reports Q4 EPS (56c), consensus (44c) Reports Q4 revenue $1.97M, consensus $3.09M. The increase in net loss was primarily attributable to higher selling, general and administrative expenses related to commercialization activities for Qsymia. In Q4, the company recognized net product revenues of $2M from sales of Qsymia.
News For VVUS From The Last 14 Days
Check below for free stories on VVUS the last two weeks.